BioCentury | Oct 3, 2016
Company News

Intrexon, Genten deal

...Intrexon granted newco Genten exclusive access to Intrexon’s ActoBiotics technology to deliver gluten peptide therapies to...
...not respond to inquiries, and Genten could not be reached. Intrexon Corp. (NYSE:XON), Germantown, Md. Genten Therapeutics Inc....
BioCentury | Oct 27, 2014
Company News

Gruenenthal management update

...CFO of the Merck Serono S.A. biopharmaceutical division of Merck KGaA ; he succeeds Stefan Genten WIR...
Items per page:
1 - 2 of 2
BioCentury | Oct 3, 2016
Company News

Intrexon, Genten deal

...Intrexon granted newco Genten exclusive access to Intrexon’s ActoBiotics technology to deliver gluten peptide therapies to...
...not respond to inquiries, and Genten could not be reached. Intrexon Corp. (NYSE:XON), Germantown, Md. Genten Therapeutics Inc....
BioCentury | Oct 27, 2014
Company News

Gruenenthal management update

...CFO of the Merck Serono S.A. biopharmaceutical division of Merck KGaA ; he succeeds Stefan Genten WIR...
Items per page:
1 - 2 of 2